All Insights
Showing 1 - 12 of 468
Regulatory Outlook
Digital Regulation | UK Regulatory Outlook November 2024
Government consults on introducing sanctions for senior executives of online platforms and marketplaces for failure to remove content on weapons
Regulatory Outlook
Data Law | UK Regulatory Outlook November 2024
Progress of the Data (Use and Access) Bill | ICO prioritising work to protect children online | ICO publishes report
Regulatory Outlook
Cyber Security | UK Regulatory Outlook November 2024
ENISA draft technical guidance on NIS2 cyber security risk management measures | DSIT call for evidence on Cyber Security and
Regulatory and compliance
What can UK business expect from regulators in future?
What can be learnt from the UK government's stated approach to regulation and growth?
Regulatory Outlook
Data law | UK Regulatory Outlook October 2024
UK government publishes Data (Use and Access) Bill | Updates from the European Data Protection Board | EU Commission publishes
Regulatory Outlook
Cyber Security | UK Regulatory Outlook October 2024
Cyber Security and Resilience Bill to be introduced in 2025 | Cyber Essentials supply chain commitment | NIS2 Directive
IT and data
GDPR for HR | ICO enforcement and the new data protection audit framework, and data privacy risks in pre-employment vetting
Welcome to this month's edition of our GDPR for HR newsletter where we dive into the latest updates, cases and
Online Safety
Online Safety Act 2023: time to prepare as UK's Ofcom confirms start of illegal content duties
Implementation is largely on schedule with only three months for risk assessments once guidance is published in December
IT and data
The UK Data (Use and Access) Bill – what businesses should be aware of
The wide-ranging bill covers much more than changes to data protection rules
IT and data
Legitimate interest as a legal ground for data processing in a commercial context in Spain
CJEU does not rule out that a commercial interest may be considered a legitimate interest for processing personal data
Life Sciences and Healthcare
Italian Medicines Agency provides clarifications in relation to the introduction of decentralised elements in clinical trials
AIFA clarifies organisational aspects, the regulatory framework and data privacy
